Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Subclinical disease revisited.

A R Kagan1, T L Morgan

  • 1Department of Radiation Oncology, University of California School of Medicine at Los Angeles, USA.

American Journal of Clinical Oncology
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dissemination and implementation strategies for physical activity guidelines among adults with disability, chronic conditions, and pregnancy: a systematic scoping review.

BMC public health·2022
Same author

Exercise is Medicine® Canada on Campus Casebook: Evaluation of a novel knowledge translation tool and lessons learned.

Evaluation and program planning·2021
Same author

Dissemination and implementation of national physical activity, sedentary behaviour, and/or sleep guidelines among community-dwelling adults aged 18 years and older: a systematic scoping review and suggestions for future reporting and research.

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme·2020
Same author

The role of radiation therapy in children with acute lymphoblastic leukemia kidney infiltration.

Medical and pediatric oncology·2001
Same author

Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.

International journal of radiation oncology, biology, physics·2001
Same author

Spinal cord compression, infection, and unknown primary cancers.

American journal of clinical oncology·2001

Adjuvant radiotherapy is commonly used for head and neck cancer to manage subclinical disease. This review critically examines evidence challenging the assumption that all residual microscopic disease requires adjuvant treatment.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Radiation Oncology

Background:

  • Adjuvant radiotherapy is standard for improving local control in postoperative patients.
  • The concept of "subclinical disease" assumes residual microscopic tumor cells necessitate adjuvant therapy.
  • Positive or close surgical margins and lymph node involvement are typical indications for adjuvant treatment.

Purpose of the Study:

  • To critically evaluate recent evidence that questions the universal need for adjuvant therapy in cases of presumed subclinical disease.
  • To reassess the fundamental assumption that all residual disease inevitably leads to local failure without adjuvant treatment.

Main Methods:

  • Literature review of recent reports and studies.
  • Critical analysis of existing assumptions regarding subclinical disease and adjuvant therapy.

Related Experiment Videos

  • Discussion of findings that challenge established treatment paradigms.

    • Main Results:

    • Emerging evidence suggests that not all patients with microscopic residual disease experience local failure if left untreated.
    • The interpretation of "close" or "microscopically positive" margins may require re-evaluation.
    • The absolute indication for adjuvant therapy based solely on these findings is being questioned.

    Conclusions:

    • The assumption that all subclinical disease requires adjuvant treatment may not hold true for all head and neck cancer patients.
    • Further research is needed to refine indications for adjuvant therapy, potentially sparing some patients from radiotherapy.
    • Personalized treatment strategies may be developed based on a more nuanced understanding of residual disease risk.